NewsMeter
NMRANeumora clears toxicology repeat in 162-animal rat study, targets NMRA-215 IND filing for Q4 2026Jul 27, 2026
MACROWarren: Crypto Clarity Act would benefit Trump and aid criminals and cartelsJul 27, 2026
MACROKremlin silent as Zelenskiy cites 30,000 North Korean troops bound for VoronezhJul 27, 2026
WORLDCXMT soars 466% on debut, briefly claiming China's most valuable listed slot in mainland's biggest IPO since 2010Jul 27, 2026
CRYPTOTriple-A treasury breach: $11.8M in losses confirmed, client funds intactJul 27, 2026
CRYPTO$52.5M crypto sale gives World fresh capital for Sam Altman's iris-scanning identity projectJul 27, 2026
ENERGYChina industrial profit growth slows again in June as oil prices retreatJul 27, 2026
WORLDHamas names Khalil al-Hayya political bureau chief after nearly two years without a leaderJul 27, 2026
NMRANeumora clears toxicology repeat in 162-animal rat study, targets NMRA-215 IND filing for Q4 2026Jul 27, 2026
MACROWarren: Crypto Clarity Act would benefit Trump and aid criminals and cartelsJul 27, 2026
MACROKremlin silent as Zelenskiy cites 30,000 North Korean troops bound for VoronezhJul 27, 2026
WORLDCXMT soars 466% on debut, briefly claiming China's most valuable listed slot in mainland's biggest IPO since 2010Jul 27, 2026
CRYPTOTriple-A treasury breach: $11.8M in losses confirmed, client funds intactJul 27, 2026
CRYPTO$52.5M crypto sale gives World fresh capital for Sam Altman's iris-scanning identity projectJul 27, 2026
ENERGYChina industrial profit growth slows again in June as oil prices retreatJul 27, 2026
WORLDHamas names Khalil al-Hayya political bureau chief after nearly two years without a leaderJul 27, 2026
News/Markets

Pomerantz LLP opens investor investigation into Larimar Therapeutics (LRMR)

The July 16, 2026 investor alert from Pomerantz LLP names Larimar Therapeutics, Inc. (NASDAQ: LRMR) as the subject of a formal securities investigation. The New York firm issued the notice via PRNewswire. No class period or alleged damages…

By Grace Osei·Jul 17, 2026·1 min read·markets

The July 16, 2026 investor alert from Pomerantz LLP names Larimar Therapeutics, Inc. (NASDAQ: LRMR) as the subject of a formal securities investigation. The New York firm issued the notice via PRNewswire. No class period or alleged damages figure appears in the published alert.

Investor contact

Pomerantz LLP identified Danielle Peyton as the designated investor contact. Shareholders seeking to participate can reach her at [email protected] or 646-581-9980, ext. 7980. The alert does not detail the scope of the inquiry or the time period at issue.

Scope of the alert

The published alert states no legal theory and names no specific regulatory filing. Investors with questions are directed to Danielle Peyton at Pomerantz LLP, the New York firm named in the PRNewswire release dated July 16, 2026.

Share
Source: NewsMeter
© 2026 NewsMeter
→

Keep reading

All news →
MarketsJul 26, 2026

10 to 15 work years left: dotcom-era scars are reshaping Gen X retirement portfolios

2 min
MarketsJul 26, 2026

Wall Street analysts name 3 stocks for long-term growth potential

1 min
MarketsJul 25, 2026

SBCF declares $0.19-per-share quarterly cash dividend, payable September 30

1 min

Key takeaways

Frequently asked

Who is being investigated and by whom?

Pomerantz LLP, a New York firm, is investigating Larimar Therapeutics, Inc. (NASDAQ: LRMR) in a formal securities investigation.

When was the investor alert issued?

The alert was issued on July 16, 2026 via PRNewswire.

How can shareholders participate or get more information?

Shareholders can contact Danielle Peyton at Pomerantz LLP by email at [email protected] or by phone at 646-581-9980, ext. 7980.

Does the alert specify a class period or damages amount?

No, the published alert contains no class period, alleged damages figure, legal theory, or named regulatory filing.